The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis

The probiotic mixture VSL#3 attenuates colitis in patients with Inflammatory Bowel Disease (IBD) and in animal models of this condition, but the mechanisms involved are incompletely understood. VSL#3 alters macrophage morphology and secretory profile in vitro in a polarization-dependent manner. We examined the effect of VSL#3 on macrophages in acute trinitrobenzene sulfonic acid-induced colitis. Rats were randomized to normal, colitis, or colitis+VSL#3 groups. After sacrifice, the colons were evaluated for macroscopic and microscopic damage. Serum cytokine levels were measured, and microbiome analysis undertaken. Total and M1 colonic macrophages, and total and proliferating hepatic macrophages were assessed by double immunofluorescence staining. Colitis+VSL#3 rats had lower macroscopic damage, with less microscopic damage in the proximal colon, compared with colitis alone. Colitis significantly increased colonic macrophage infiltration, which was significantly reduced by VSL#3 treatment. VSL#3 did not decrease the colitis-induced surge of colonic M1 macrophages or hepatic macrophages. VSL#3 reduced colitis-induced serum cytokine levels, and induced restoration of colonic transcript levels for pro-inflammatory, anti-inflammatory, and barrier proteins to, or past, normal levels. Fecal bacteria distribution changed between groups. In summary, the probiotic VSL#3 reduces colitis severity, colonic macrophage infiltration, and serum cytokine levels, but does not dampen the pro-inflammatory phenotype of M1 macrophages.

[1]  C. Appleyard,et al.  Colonic macrophage polarization in homeostasis, inflammation, and cancer. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[2]  Á. Corbí,et al.  CD163L1 and CLEC5A discriminate subsets of human resident and inflammatory macrophages in vivo , 2015, Journal of leukocyte biology.

[3]  C. Appleyard,et al.  Double immunofluorescent staining of rat macrophages in formalin-fixed paraffin-embedded tissue using two monoclonal mouse antibodies , 2015, Histochemistry and Cell Biology.

[4]  James Kinross,et al.  The gut microbiota and host health: a new clinical frontier , 2015, Gut.

[5]  J. Kabeerdoss,et al.  Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid , 2015, The Indian journal of medical research.

[6]  S. Fiorucci,et al.  Inhibition of Chronic Ulcerative Colitis-associated Adenocarcinoma Development in Mice by VSL#3 , 2015, Inflammatory bowel diseases.

[7]  W. D. de Vos,et al.  Akkermansia muciniphila Adheres to Enterocytes and Strengthens the Integrity of the Epithelial Cell Layer , 2015, Applied and Environmental Microbiology.

[8]  F. Geissmann,et al.  Correction: Corrigendum: Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice , 2014, Nature Immunology.

[9]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[10]  J. W. Lee,et al.  Amelioration of DSS-induced murine colitis by VSL#3 supplementation is primarily associated with changes in ileal microbiota composition. , 2014, Gut microbes.

[11]  C. Appleyard,et al.  The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner , 2014, Journal of clinical & cellular immunology.

[12]  Y. Belkaid,et al.  Microbiota-Dependent Crosstalk Between Macrophages and ILC3 Promotes Intestinal Homeostasis , 2014, Science.

[13]  E. El-Omar,et al.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? , 2014, World journal of gastroenterology.

[14]  T. Hibi,et al.  Macrophages and Dendritic Cells Emerge in the Liver during Intestinal Inflammation and Predispose the Liver to Inflammation , 2014, PloS one.

[15]  Zhixiang Zuo,et al.  Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohn's Disease, and Pouchitis: Meta-analysis of Randomized Controlled Trials , 2014, Inflammatory bowel diseases.

[16]  B. Kempkes,et al.  Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages , 2013, PloS one.

[17]  J. Esplugues,et al.  M2 Macrophages Activate WNT Signaling Pathway in Epithelial Cells: Relevance in Ulcerative Colitis , 2013, PloS one.

[18]  T. Hibi,et al.  A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. , 2013, Cell host & microbe.

[19]  D. McKay,et al.  Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: participation of IL-10. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[20]  Ansuman T. Satpathy,et al.  Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. , 2012, Immunity.

[21]  B. Malissen,et al.  CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1‐inducing role of mesenteric lymph node macrophages during colitis , 2012, European journal of immunology.

[22]  Francisco Guarner,et al.  The gut microbiota in IBD , 2012, Nature Reviews Gastroenterology &Hepatology.

[23]  B. Malissen,et al.  Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors , 2012, Mucosal Immunology.

[24]  T. Lagerweij,et al.  Gene Expression Profiling Identifies Mechanisms of Protection to Recurrent Trinitrobenzene Sulfonic Acid Colitis Mediated by Probiotics , 2012, Inflammatory bowel diseases.

[25]  B. Kuster,et al.  Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. , 2012, Cell host & microbe.

[26]  J. Bassaganya-Riera,et al.  Immunoregulatory Mechanisms Underlying Prevention of Colitis-Associated Colorectal Cancer by Probiotic Bacteria , 2012, PloS one.

[27]  Richard Hansen,et al.  IBD—what role do Proteobacteria play? , 2012, Nature Reviews Gastroenterology &Hepatology.

[28]  P. Rutgeerts,et al.  Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro , 2012, Inflammatory bowel diseases.

[29]  H. Vogel,et al.  Probiotic Bacteria Produce Conjugated Linoleic Acid Locally in the Gut That Targets Macrophage PPAR γ to Suppress Colitis , 2012, PloS one.

[30]  R. Giannella,et al.  Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease , 2012, Expert Review of Clinical Immunology.

[31]  A. Rivollier,et al.  Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon , 2012, The Journal of experimental medicine.

[32]  C. Jobin,et al.  Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[33]  J. Kao,et al.  Intestinal dysbiosis in inflammatory bowel disease , 2011, Gut microbes.

[34]  Werner Müller,et al.  Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. , 2011, Immunity.

[35]  K. Honda,et al.  Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species , 2011, Science.

[36]  A. Fodor,et al.  Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS‐induced colitis , 2011, Inflammatory bowel diseases.

[37]  K. Takeda,et al.  Commensal microbiota induce LPS hyporesponsiveness in colonic macrophages via the production of IL-10. , 2010, International immunology.

[38]  E. Verna,et al.  Use of probiotics in gastrointestinal disorders: what to recommend? , 2010, Therapeutic advances in gastroenterology.

[39]  D. Sester,et al.  An Independent Subset of TLR Expressing CCR2-Dependent Macrophages Promotes Colonic Inflammation , 2010, The Journal of Immunology.

[40]  D. McKay,et al.  In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. , 2010, Gastroenterology.

[41]  D. Haller,et al.  Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease , 2009, Inflammatory bowel diseases.

[42]  N. Senninger,et al.  Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[43]  L. Guan,et al.  Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study , 2009, Inflammatory bowel diseases.

[44]  S. Gordon,et al.  Alternative activation of macrophages: an immunologic functional perspective. , 2009, Annual review of immunology.

[45]  T. Hibi,et al.  Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. , 2008, The Journal of clinical investigation.

[46]  C. Appleyard,et al.  An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis , 2008, Regulatory Peptides.

[47]  C. Appleyard,et al.  Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitis-associated colon cancer. , 2007, Cancer research.

[48]  P. Brigidi,et al.  High-Dose Probiotics for the Treatment of Active Pouchitis , 2007, Diseases of the colon and rectum.

[49]  Wendy S. Garrett,et al.  Communicable Ulcerative Colitis Induced by T-bet Deficiency in the Innate Immune System , 2007, Cell.

[50]  T. Churchill,et al.  Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis , 2007, Hepatology.

[51]  Idhaliz Flores,et al.  Molecular profiling of a rat model of colitis: Validation of known inflammatory genes and identification of novel disease‐associated targets , 2006, Inflammatory bowel diseases.

[52]  S. Miehlke,et al.  Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. , 2006, Journal of medical microbiology.

[53]  R. Ley,et al.  Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine , 2006, Cell.

[54]  M. Kamm,et al.  Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis , 2006, Gut.

[55]  R. Bibiloni,et al.  VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis , 2005, The American Journal of Gastroenterology.

[56]  J. Orenstein,et al.  Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. , 2005, The Journal of clinical investigation.

[57]  A. Macpherson,et al.  Induction of Protective IgA by Intestinal Dendritic Cells Carrying Commensal Bacteria , 2004, Science.

[58]  S. Akira,et al.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. , 2004, Gastroenterology.

[59]  P. Brigidi,et al.  Variable Response to Probiotics in Two Models of Experimental Colitis in Rats , 2002, Inflammatory bowel diseases.

[60]  C. De Simone,et al.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function. , 2001, Gastroenterology.

[61]  P. Brigidi,et al.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[62]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.

[63]  P. Brigidi,et al.  Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis , 1999, Alimentary pharmacology & therapeutics.

[64]  J. Wallace,et al.  Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. , 1995, The American journal of physiology.

[65]  J. Wallace,et al.  Hapten-induced model of chronic inflammation and ulceration in the rat colon. , 1989, Gastroenterology.

[66]  S. Lee,et al.  Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80 , 1985, The Journal of experimental medicine.

[67]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[68]  D. Hommes,et al.  Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner. , 2011, Gastroenterology.